This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides: Center for International Blood & Marrow Transplant Research; 2020 [updated 2020. Available from: https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx.
Hill JA, Mayer BT, Xie H, Leisenring WM, Huang M-L, Stevens-Ayers T, et al. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017;129:2316–25.
Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res. 2009;33:384–90.
Lee KH, Gowrishankar K, Street J, McGuire HM, Luciani F, Hughes B, et al. Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection. Clin Transl Immunol. 2020;9:e1200.
Castellano-González G, McGuire HM, Luciani F, Clancy LE, Li Z, Avdic S, et al. Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity. Blood Adv. 2020;4:3443–56.
Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, et al. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Adv. 2022;6:4949–66.
Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134:17–32.
McGuire HM, Rizzetto S, Withers BP, Clancy LE, Avdic S, Stern L, et al. Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells. Clin Transl Immunol. 2020;9:e1149.
Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6:ra83.
Spyridoula V, Anne MT, Manik K, Shivani SM, Ayumi W, Premal L, et al. Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2020;105:235–43.
Gottlieb DJ, Clancy LE, Withers B, McGuire HM, Luciani F, Singh M, et al. Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant. Clin Transl Immunol. 2021;10:e1249.
Ma CK, Blyth E, Clancy L, Simms R, Burgess J, Brown R, et al. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2015;17:1406–20.
Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.
Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, et al. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study. Leukemia. 2020;34:831–44.
Huisman W, Roex MCJ, Hageman L, Koster EAS, Veld SAJ, Hoogstraten C, et al. Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing. Blood Adv. 2023;7:812–27.
This study was funded by the Australian National Health and Medical Research Council (NHMRC) (PG1088118). E.B. was an NHMRC Early Career Fellow (ECF1089398), a NSW Cancer Institute Early Career Fellow (ECF181576) and a current NSW Health Cell and Gene Therapy Fellow. WJ was supported by a scholarship from the Haematology Society of Australia and New Zealand and Leukaemia Foundation Australia, and is a current Leukaemia Foundation Australia Fellow. We are grateful to Gillian Huang and Elissa Atkins for clinical trial management. Microchimerism assays, DNA quantification, and flow cytometry were performed at the Westmead Scientific Platforms, which are supported by the Westmead Research Hub, the Westmead Institute for Medical Research the Cancer Institute of New South Wales, the National Health and Medical Research Council, and the Ian Potter Foundation.
LEC, KM, EB, and DJG hold patents in adoptive cell therapy for opportunistic infection and malignancy. EB declares advisory board membership for IQVIA, Abbvie, MSD, Astellas, Novartis, BMS, Bastion Education and research funding from MSD. The remaining authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jiang, W., Avdic, S., Lee, K.H. et al. Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study). Leukemia 37, 2330–2333 (2023). https://doi.org/10.1038/s41375-023-02033-5